With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125
microns in diameter, has left an indelible impact on our world. With the paucity of new drugs …

Abstract The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the
researchers to strive to develop drugs or vaccines to prevent or halt the progression of this …

Introduction At this time, there is no specific therapeutic or vaccine for treatment of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for …

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus
designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in …

The SARS-Cov-2 virus, emerged in December 2019 in Wuhan, China and has now spread
to all parts of the world. Many research groups are carrying out intense research on drugs …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Background Favipiravir possesses high utility for treating patients with COVID-19. However,
research examining the efficacy and safety of favipiravir for patients with COVID-19 is …

Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …